Despite the advances made in the molecular description of the pathogenesis of CALR-mutated ET and PMF, so far it has not been possible to develop any targeted therapy capable of curing these diseases or reducing the mutant allele burden in these patients. This evidence concerns the gene CALR and essential thrombocythemia.